Pennsylvania House Of Representatives Calls For The FDA To Do It's Job And Establish Proper Regulations For Kratom, Something That The FDA Has Refused To Do For Years
The Food and Drug Administration (FDA) has the responsibility of ensuring that every food, supplement, and drug in America is properly regulated in order to make sure that only safe and sanitary products reach consumers. However, the FDA has refused to do its job when it comes to Kratom.
Now the Pennsylvania House of Representatives has become perhaps the first government agency to demand that the FDA does it’s job and establish proper regulations for Kratom.
Specifically, Pennsylvania House Resolution 460 states “RESOLVED, That the House of Representatives of the Commonwealth of Pennsylvania urge the United States Food and Drug Administration to promptly consider guidelines and protocols for the safe use of kratom; and be it further RESOLVED, That a copy of this resolution be transmitted to the headquarters of the United States FDA”.
Notably, the text of this resolution describes the Kratom situation in-depth, including how the FDA has issued warnings about Kratom and has called for Kratom to be banned, but Kratom remains legal due to an outpouring from Kratom advocates. Further, the resolution even discusses how the FDA list of ‘Kratom related deaths‘ are due to polydrug abuse and not proven to be from Kratom itself.
Basically, the Pennsylvania House of Representatives is pointing out that although the FDA is anti-Kratom, people are using Kratom on a mass scale, and therefore proper regulations are needed, rather than the FDA ignoring Kratom just because they don’t like Kratom.
Indeed, the American Kratom Association has been dealing with this exact issue via the Kratom Consumer Protection Act (KCPA), which requires Kratom manufacturers to follow FDA Good Manufacturing Practices (GMP) guidelines, including using completely sanitary methods to ensure that the Kratom is not contaminated, and lab testing to guarantee that the Kratom is not adulterated or contaminated.
The KCPA is critical, because without proper regulations like the KCPA offers, then Kratom that is adulterated with synthetic drugs or simply contaminated with bacteria could end up harming end users.
However, ultimately the FDA should be doing exactly what the KCPA is trying to do, which is why the Pennsylvania House of Representatives is bringing this issue into the spotlight.
All of this being said, it really is a double edged sword if the FDA establishes Kratom regulations. Since the FDA is so anti-Kratom, it seems probable that they would design Kratom regulations in a way which would severely inhibit the Kratom industry. Essentially, although it is important to note that the FDA hasn’t been doing its job with regards to Kratom, and now the State of Pennsylvania is asking the FDA to do its job, we may be better off in the current situation where the FDA has not established regulations.
In-fact, the best case scenario is that the KCPA gets passed nationwide, since the KCPA offers fair, rigorous, and balanced Kratom regulations which ensure safety for the end user while simultaneously ensuring that the Kratom industry can continue to proliferate. Compare this to whatever regulations the FDA could possibly mandate, regulations which would probably aim to blow the knees out of the Kratom industry, and that would be bad for both Kratom users and vendors.